Nemaura Medical Inc. (NMRD) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerNemaura Medical Inc. (NMRD) trades at $0.0001. Nemaura Medical Inc. is a medical technology company focused on developing and manufacturing non-invasive continuous glucose monitoring (CGM) systems. Sector: Healthcare.
Price as of · Last analyzed: Mar 15, 2026Analyst Coverage for NMRD: NMRD does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Nemaura Medical Inc. (NMRD) Healthcare & Pipeline Overview
Nemaura Medical Inc. develops and manufactures the sugarBEAT non-invasive continuous glucose monitoring (CGM) system, targeting individuals with Type I and Type II diabetes and pre-diabetic patients. The company's focus on non-invasive technology differentiates it in the competitive medical device market, offering a potential alternative to traditional CGM methods.
What Is the Investment Thesis for NMRD?
Nemaura Medical Inc. presents a notable research candidate within the medical device sector, driven by the increasing prevalence of diabetes and the demand for non-invasive glucose monitoring solutions. The company's sugarBEAT product offers a potential alternative to traditional CGM systems, appealing to patients seeking a more convenient and painless monitoring experience. Key value drivers include the expansion of sugarBEAT's market reach, regulatory approvals in key geographies, and the successful implementation of diabetes prevention and reversal programs. However, investors may want to evaluate the company's limited financial resources, reliance on regulatory approvals, and competition from established players in the CGM market. The company's beta of -117.34 indicates high volatility.
Based on FMP financials and quantitative analysis
NMRD Key Highlights
Nemaura Medical Inc. focuses on non-invasive continuous glucose monitoring (CGM) technology.
- The company's primary product is sugarBEAT, a non-invasive CGM device.
- Nemaura Medical also offers proBEAT, a wellness guidance program.
- The company targets individuals with Type I and Type II diabetes, as well as pre-diabetic patients.
- Nemaura Medical Inc. was founded in 2009 and is based in New York.
Who Are NMRD's Competitors?
NMRD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ABT Abbott Laboratories | $100.32 | +2.89% | $169B | 70 5-pillar |
| DXCM DexCom, Inc. | $87.02 | +1.94% | $32.2B | 96 5-pillar |
| BJDX Bluejay Diagnostics, Inc. | $0.78 | -6.77% | 30 5-pillar | |
| NVNO enVVeno Medical Corporation | $7.87 | -2.90% | $5.63M | 30 5-pillar |
| BDMD Baird Medical Investment Holdings Limited | $0.78 | +4.37% | $32.1M | — |
| SNWV SANUWAVE Health, Inc. | $4.82 | -0.21% | $41.5M | 36 5-pillar |
| SRTS Sensus Healthcare, Inc. | $2.98 | -0.34% | $49.1M | 31 5-pillar |
| HYPD Hyperion DeFi, Inc. | $3.82 | +2.51% | $56.5M | 36 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NMRD's Key Strengths?
Non-invasive CGM technology.
- Focus on diabetes prevention and reversal.
- Wellness guidance program (proBEAT).
- Established presence in the US market.
What Are NMRD's Weaknesses?
Limited financial resources.
- Reliance on regulatory approvals.
- Competition from established players.
- Small employee count (36).
What Are the Key Risks for NMRD?
Financial-distress signal — its Altman Z-Score of -23.47 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 3 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Competition from established players in the CGM market.
- Technological advancements by competitors.
- Changes in regulatory requirements.
- Limited financial resources.
- Reliance on regulatory approvals.
What Are NMRD's Competitive Advantages?
- Proprietary non-invasive CGM technology.
- Established brand reputation in the non-invasive glucose monitoring market.
- Strong relationships with healthcare providers and diabetes management organizations.
- Intellectual property protection for sugarBEAT technology.
What Does NMRD Do?
Nemaura Medical Inc., established in 2009 and headquartered in New York, is a medical technology company specializing in the development and manufacturing of continuous glucose monitoring (CGM) systems. The company's flagship product, sugarBEAT, is a non-invasive CGM device designed for use by individuals with Type I and Type II diabetes, as well as for screening pre-diabetic patients. Unlike traditional CGM systems that require inserting a sensor under the skin, sugarBEAT utilizes a skin patch to measure glucose levels non-invasively. In addition to sugarBEAT, Nemaura Medical offers proBEAT, a wellness guidance program that provides users with personalized insights and education on factors affecting their blood sugar profiles. This program aims to empower users to make informed lifestyle choices and manage their blood sugar levels effectively. Nemaura also conducts diabetes prevention and reversal programs, further expanding its reach in the diabetes management market. The company's focus on non-invasive technology and comprehensive diabetes management solutions positions it as a player in the evolving healthcare landscape.
What Products and Services Does NMRD Offer?
- Develop and manufacture non-invasive continuous glucose monitoring (CGM) systems.
- Offer sugarBEAT, a non-invasive CGM device for individuals with diabetes and pre-diabetes.
- Provide proBEAT, a wellness guidance program for managing blood sugar levels.
- Conduct diabetes prevention and reversal programs.
- Focus on providing painless and convenient glucose monitoring solutions.
- Target individuals with Type I and Type II diabetes, as well as pre-diabetic patients.
How Does NMRD Make Money?
- Sales of sugarBEAT CGM devices and related accessories.
- Subscription fees for the proBEAT wellness guidance program.
- Revenue from diabetes prevention and reversal programs.
- Partnerships with healthcare providers and diabetes management organizations.
What Industry Does NMRD Operate In?
The medical device industry is experiencing growth, driven by technological advancements and an aging global population. The market for continuous glucose monitoring (CGM) systems is particularly expanding due to the rising prevalence of diabetes and the increasing adoption of CGM technology for diabetes management. Nemaura Medical Inc. operates in this competitive landscape, facing competition from established players like Abbott and Dexcom, as well as emerging companies developing innovative CGM solutions. The company's focus on non-invasive technology differentiates it in the market, offering a potential advantage in attracting patients seeking a more convenient and painless monitoring experience.
Who Are NMRD's Key Customers?
- Individuals with Type I diabetes.
- Individuals with Type II diabetes.
- Pre-diabetic patients.
- Healthcare providers.
- Diabetes management organizations.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Insider Activity
12 transactions · 1 purchases, 0 sales, 11 other transactions · 8 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Key Financial Metrics
Return on equity for Nemaura Medical Inc. stands at 249.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -97.1%, showing how much profit it generates from its asset base. A current ratio of 0.61 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Nemaura Medical Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -23.47 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
Nemaura Medical Inc. has missed Wall Street's EPS estimate in 3 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 6.8% above estimates on average.
Forward Outlook
Wall Street analysts project Nemaura Medical Inc. revenue of about $3.4M for fiscal 2026, with EPS near $-0.34.
Company Profile
Nemaura Medical Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in New York City, US. The company is led by CEO Dewan Fazlul Hoque Chowdhury. NMRD has traded publicly since 2018.
NMRD Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
NMRD Latest News
-
Stocks That Hit 52-Week Lows On Monday
· Jan 27, 2020
-
Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 18, 2018
· Dec 19, 2018
NMRD Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for NMRD.
Price Targets
Wall Street price target analysis for NMRD.
NMRD MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for NMRD; grades run from A+ (80-100) to F (below 30).
NMRD OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, encompassing securities that are not eligible for quotation on OTCQX or OTCQB. Companies in this tier often face challenges in meeting minimum financial standards, disclosure requirements, or corporate governance criteria. Investing in OTC Other securities carries significant risks due to the limited information available and the potential for fraud or manipulation. These securities may also be subject to state securities laws, adding another layer of complexity for investors. Companies in this tier may be defunct or experiencing severe financial distress.
- OTC Tier: OTC Other
- Limited financial information and disclosure.
- Low trading volume and liquidity.
- Potential for fraud or manipulation.
- Higher risk of financial distress or bankruptcy.
- Limited regulatory oversight.
- Verify the company's registration and compliance with securities laws.
- Review the company's financial statements, if available.
- Assess the company's business model and competitive landscape.
- Evaluate the company's management team and track record.
- Understand the risks associated with investing in OTC Other securities.
- Consult with a qualified financial advisor.
- Check for any regulatory actions or legal proceedings against the company.
- Company has been in operation since 2009.
- Focus on a specific niche market (non-invasive CGM).
- Has a developed product (sugarBEAT).
- Has patents or other intellectual property protection.
Nemaura Medical Inc. Healthcare Stock: Key Questions Answered
What are the main risks for NMRD?
Nemaura Medical Inc. faces several risks, including competition from established players in the CGM market like Abbott and Dexcom, who have greater resources and market share.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited financial data available.
- OTC stock carries higher risk.
- Analyst coverage is sparse.